China's TopRidge Pharma has agreed to produce more than 100 million doses of Russia's two-shot Sputnik V vaccine against COVID 19, the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) said on Thursday.

The fund, which markets Sputnik V globally, said the two sides planned to cooperate on clinical trials in China and to promote its use there.